Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial
Julie Rask Larsen, Louise Vedtofte, Jens Juul Holst, Peter Oturai, Andreas Kjær, Christoph U Correll, Tina Vilsbøll, Anders Fink-Jensen, Julie Rask Larsen, Louise Vedtofte, Jens Juul Holst, Peter Oturai, Andreas Kjær, Christoph U Correll, Tina Vilsbøll, Anders Fink-Jensen
Abstract
Background: Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionally, patients with schizophrenia-spectrum disorders not infrequently consume alcohol. Glucagon-like peptide-1 (GLP-1) has shown to improve glycaemic control and reduce alcohol intake among patients with type 2 diabetes.
Objectives: To investigate whether the beneficial effects of GLP-1 analogues on glycaemic control and alcohol intake, in patients with type 2 diabetes, can be extended to a population of pre-diabetic psychiatric patients receiving antipsychotic treatment.
Methods and analysis: Trial design, intervention and participants: The study is a 16-week, double-blinded, randomised, parallel-group, placebo-controlled clinical trial, designed to evaluate the effects of the GLP-1 analogue liraglutide on glycaemic control and alcohol intake compared to placebo in patients who are prediabetic, overweight (body mass index ≥27 kg/m(2)), diagnosed with a schizophrenia-spectrum disorder and on stable treatment with either clozapine or olanzapine.
Outcomes: The primary endpoint is the change in glucose tolerance from baseline (measured by area under the curve for the plasma glucose excursion following a 4 h 75 g oral glucose tolerance test) to follow-up at week 16. The secondary endpoints include changes of dysglycaemia, body weight, waist circumference, blood pressure, secretion of incretin hormones, insulin sensitivity and β cell function, dual-energy X-ray absorption scan (body composition), lipid profile, liver function and measures of quality of life, daily functioning, severity of the psychiatric disease and alcohol consumption from baseline to follow-up at week 16. Status: Currently recruiting patients.
Ethics and dissemination: Ethical approval has been obtained. Before screening, all patients will be provided oral and written information about the trial. The study will be disseminated by peer-review publications and conference presentations.
Trial registration number: ClinicalTrials.gov: NCT01845259, EudraCT: 2013-000121-31.
Keywords: MENTAL HEALTH.
Figures
References
- De HM, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52–77
- De HM, Detraux J, van WR, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114–26
- Krane-Gartiser K, Breum L, Glumrr C, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 2011;65:345–52
- Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011;17:97–107
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409–39
- Vilsboll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115–21
- Astrup A, Rossner S, Van GL, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606–16
- Holten MK, Zacho M, Gaster M, et al. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 2004;53:294–305
- Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother 2010;10:1175–200
- Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-harmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140:159–68
- Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594–602
- Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;(12):CD006629.
- Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 2011;128:166–70
- Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31–41
- Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520–30
- Bagger JI, Christensen M, Knop FK, et al. Therapy for obesity based on gastrointestinal hormones. Rev Diabet Stud 2011;8:339–47
- Lubman DI, King JA, Castle DJ. Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry 2010;22:191–201
- Egecioglu E, Steensland P, Fredriksson I, et al. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 2013;38:1259–70
- Kalra S, Kalra B, Sharma A. Change in alcohol consumption following liraglutide initiation: a real-life experience. American Diabetes Association Scientific Sessions 2011, Abstract number: 1029–P.
Source: PubMed